Home
Frode Selheim's picture

Frode Selheim

Professor
  • E-mailFrode.Selheim@uib.no
  • Phone+47 477 52 359
  • Visitor Address
    Jonas Lies vei 91
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. The constitutive extracellular protein release by acute myeloid leukemia cells—A proteomic study of patient heterogeneity and its modulation by mesenchymal stromal cells. Cancers. 1-26.
  • Show author(s) 2021. Proteomic comparison of bone marrow derived osteoblasts and mesenchymal stem cells. International Journal of Molecular Sciences.
  • Show author(s) 2021. Effects of the autophagy‐inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. Journal of Personalized Medicine. 1-23.
  • Show author(s) 2020. The progression of acute myeloid leukemia from first diagnosis to chemoresistant relapse: A comparison of proteomic and phosphoproteomic profiles. Cancers. 1-13.
  • Show author(s) 2020. The extracellular bone marrow microenvironment — a proteomic comparison of constitutive protein release by in vitro cultured osteoblasts and mesenchymal stem cells. Cancers.
  • Show author(s) 2020. Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. Cancers.
  • Show author(s) 2020. Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation. Aging. 24734-24777.
  • Show author(s) 2019. The capacity of long-term in vitro proliferation of acute myeloid leukemia cells supported only by exogenous cytokines is associated with a patient subset with adverse outcome. Cancers. 1-22.
  • Show author(s) 2019. Proteomic profiling of primary human acute myeloid leukemia cells does not reflect their constitutive release of soluble mediators. Proteomes. 1-10.
  • Show author(s) 2019. Proteome and phosphoproteome changes associated with prognosis in acute myeloid leukemia. bioRxiv - the preprint server for biology.
  • Show author(s) 2019. Protein expression profiling of plasma and lungs at different stages of metastatic development in a human triple negative breast cancer xenograft model. PLOS ONE.
  • Show author(s) 2019. Mice depleted for Exchange Proteins Directly Activated by cAMP (Epac) exhibit irregular liver regeneration in response to partial hepatectomy. Scientific Reports. 1-17.
  • Show author(s) 2019. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.
  • Show author(s) 2019. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer. 545-555.
  • Show author(s) 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Show author(s) 2018. Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome. International Journal of Molecular Sciences. 1-11.
  • Show author(s) 2018. Mathematical modelling of nitric oxide/cyclic GMP/cyclic AMP signalling in platelets. International Journal of Molecular Sciences. 1-21.
  • Show author(s) 2018. Insulin-Like Growth Factor-I as an Effector Element of the Cytokine IL-4 in the Development of a Leishmania major Infection. Mediators of Inflammation.
  • Show author(s) 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Show author(s) 2017. Increased microvascular permeability in mice lacking Epac1 (Rapgef3). Acta Physiologica. 441-452.
  • Show author(s) 2017. Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIbβ expression. Scientific Reports. 1-15.
  • Show author(s) 2016. The past, present and future subclassification of patients with acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 6-19.
  • Show author(s) 2016. Systemic Analysis of Regulated Functional Networks. Methods in molecular biology. 287-310.
  • Show author(s) 2016. Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biological Procedures Online. 1-10.
  • Show author(s) 2016. Practical considerations for omics experiments in biomedical sciences. Current Pharmaceutical Biotechnology. 105-114.
  • Show author(s) 2016. Global cell proteome profiling, phospho-signaling and quantitative proteomics for identification of new biomarkers in acute myeloid leukemia patients. Current Pharmaceutical Biotechnology. 52-70.
  • Show author(s) 2016. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. Journal of Proteomics. 214-225.
  • Show author(s) 2015. Drug repurposing: Sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc<sup>-</sup>, leading to glutathione depletion. Oncogene. 5951-5959.
  • Show author(s) 2014. Time-dependent inhibitory effects of cGMP-analogues on thrombin-induced platelet-derived microparticles formation, platelet aggregation, and P-selectin expression. Biochemical and Biophysical Research Communications - BBRC. 357-363.
  • Show author(s) 2014. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
  • Show author(s) 2013. Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical and Biophysical Research Communications - BBRC. 603-608.
  • Show author(s) 2013. Iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from streptosporangium sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells. Marine Drugs. 332-349.
  • Show author(s) 2013. Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium. Journal of Proteome Research. 134-149.
  • Show author(s) 2012. Minimization of side reactions during Lys Tag derivatization of C-terminal lysine peptides. Analytica Chimica Acta. 101-107.
  • Show author(s) 2011. Nostocyclopeptide-M1: A potent, nontoxic inhibitor of the hepatocyte drug transporters OATP1B3 and 1B1. Molecular Pharmaceutics. 360-367.
  • Show author(s) 2011. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change. Platelets. 8-19.
  • Show author(s) 2010. Marine Benthic Cyanobacteria Contain Apoptosis-Inducing Activity Synergizing with Daunorubicin to Kill Leukemia Cells, but not Cardiomyocytes. Marine Drugs. 2659-2672.
  • Show author(s) 2010. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change. Platelets. 7-18.
  • Show author(s) 2010. A novel cyanobacterial nostocyclopeptide is a potent antitoxin against microcystins. ChemBioChem. 1594-1599.
  • Show author(s) 2009. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia Research. 276-287.
  • Show author(s) 2009. Epac-induced Alterations in the Proteome of Human SH-SY5Y Neuroblastoma Cells. Journal of Proteomics & Bioinformatics. 244-245.
  • Show author(s) 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • Show author(s) 2005. Neuro-apoptogenic and blood platelet targeting toxins in benthic marine cyanobacteria from the Portuguese coast. Aquatic Toxicology. 294-306.
  • Show author(s) 2005. A high proportion of Baltic Sea benthic cyanobacterial isolates contain apoptogens able to induce rapid death of isolated rat hepatocytes. Toxicon. 252-260.
  • Show author(s) 2004. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood. 2775-2782.
  • Show author(s) 2003. cAMP effector mechanisms. Novel twists for an "old" signaling system. FEBS Letters. 121-126.
  • Show author(s) 2003. cAMP analog mapping of Epac1 and camp kinase: discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. Journal of Biological Chemistry. 35394-35402.
  • Show author(s) 2002. Identification of functional VEGF receptors on human platelets. FEBS Letters. 107-110.
  • Show author(s) 2001. Alterations in platelet phospholipid metabolism by substances from a marine microalgae. Chemistry and Physics of Lipids. 139-140.
  • Show author(s) 2000. Platelet-derived-growth-factor-induced signalling in human platelets: phosphoinositide-3-kinase-dependent inhibition of platelet activation. Biochemical Journal. 469-475.
  • Show author(s) 2000. Platelet-derived-growth-factor-induced signalling in human platelets: phosphoinositide-3-kinase-dependent inhibition of platelet activation. Biochemical Journal. 469-475.
  • Show author(s) 2000. PI 3-kinase signalling in platelets: the significance of synergistic, autocrine stimulation. Platelets. 69-82.
  • Show author(s) 2000. PI 3-kinase signalling in platelets: the significance of synergistic, autocrine stimulation. Platelets. 69-82.
  • Show author(s) 2000. Adrenaline potentiates PI 3-kinase in platelets stimulated with thrombin and SFRLLN: role of secreted ADP. The FEBS Journal. 62-66.
  • Show author(s) 2000. Adrenaline potentiates PI 3-kinase in platelets stimulated with thrombin and SFRLLN: role of secreted ADP. FEBS Letters. 62-66.
  • Show author(s) 1999. S:Platelet-derived growth factor (PDGF) inhibits platelet activation in whole blood. Thrombosis Research. 185-196.
  • Show author(s) 1999. Platelet-Derived Growth Factor Inhibits Platelet Activation in Heparinized Whole Blood. Thrombosis Research. 185-196.
  • Show author(s) 1999. Formation of PI 3-kinase products in platelets by thrombin, but not by collagen, is dependent on synergistic autocrine activation stimulation, particularly through secreted ADP. Biochemical and Biophysical Research Communications - BBRC. 780-785.
  • Show author(s) 1999. Formation of PI 3-Kinase Products in Platelets by Thrombin, but Not Collagen, is Dependent on Synergistic Autocrine Stimulation, Particularly through Secreted ADP. Biochemical and Biophysical Research Communications - BBRC. 780-785.
  • Show author(s) 1996. Effect of platelet derived growth factor on platelets, an example of autocrine inhibition. Platelets. 360-361.
Report
  • Show author(s) 2005. The cAMP Receptors Epac and PKA synergize to induce PC12 cell neuritogenesis and to protect against apoptosis. .
  • Show author(s) 2000. Venlafaxine Treatment Stimulates Blood Platelet Activity. 5. 5. .
Academic lecture
  • Show author(s) 2009. Proteomikk nettverket. Hvordan er det organisert og hva kan vi tilby.
  • Show author(s) 2009. Proteomic-plattformen - PROBE.
  • Show author(s) 2003. cAMP effector mechanisms. Novel twists for an "old" signalling system.
  • Show author(s) 2002. New apoptosis-modulating substances from marine microalgae.
Editorial
  • Show author(s) 2019. Targeted and Immune-Based Therapies for Acute Myeloid Leukemia: Inflammatory Signaling and Multiple Post-Translational Modifications. Current Medicinal Chemistry. 5242-5243.
  • Show author(s) 2016. Toward personalized treatment for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 4-5.
  • Show author(s) 2016. Editorial: Toward Personalized Treatment for Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 4-5.
  • Show author(s) 2006. Proteomic Technologies in Translational Medicine. Current Pharmaceutical Biotechnology. 133-133.
Thesis at a second degree level
  • Show author(s) 1995. c-fos mRNA prosessing i nomale og tumorigne C3H/10T1/2 celler. Hovedoppgave (cand.scient.).
Masters thesis
  • Show author(s) 2017. Optimization of Sample Preparation for Mass Spectrometry-Based Quantitative Analysis of All-Trans Retinoic Acid and Valproic Acid Treated Acute Myeloid Leukemia Patients.
  • Show author(s) 2012. Mass spectrometry-based proteomics of human cerebrospinal fluid Biomarker discovery and verification in multiple sclerosis.
  • Show author(s) 2012. Inhibition of platelet surface expression of P-selectin by site-selective synergistic pairs of cAMP Analogs.
  • Show author(s) 2012. Glycoproteomics in Human Cerebrospinal Fluid Mapping the CSF Proteome, and Biomarker Discovery and Qualification in Multiple Sclerosis.
  • Show author(s) 2011. Proteomics in Cerebrospinal fluid: Finding proteins highly enriched in CSF, proteins influenced by the rostro-caudal gradient, and biomarker verification in Multiple Sclerosis.
  • Show author(s) 2011. A proteomics study of Cerebrospinal fluid in relation to biomarker discovery and verification in Multiple Sclerosis, with emphasis on the effect of pre-analytical factors.
  • Show author(s) 2008. Quantitative proteomics of Epac signaling in differentiating human SH-SY5Y neuroblastoma cells.
  • Show author(s) 2008. Platelet inhibitory compounds from marine microorganisms.
  • Show author(s) 2008. Epac-induced neuronal differentiation of Human SH-SY5Y neuroblastoma cells.
  • Show author(s) 2005. The functional quality of INTERCEPT – treated platelets during storage.
  • Show author(s) 2005. Cyclic AMP dependent protein kinase (cAPK) and exchange protein directly activated by cAMP (Epac) signaling in Rat pheochromocytoma PC12 and Human Neuroblastma SH-SY5Y cell line.
Letter to the editor
  • Show author(s) 2017. Rethinking the role of osteopontin in human acute myeloid leukemia. Leukemia and Lymphoma. 1494-1497.
Doctoral dissertation
  • Show author(s) 1999. Autocrine signalling and PDGF-induced inhibition of human platelet activation. -.
Academic chapter/article/Conference paper
  • Show author(s) 2016. Interpretation of Quantitative Shotgun Proteomic Data. 14 pages.
Poster
  • Show author(s) 2010. Peptide Side-Products of Lys Tag Derivatization reaction.
  • Show author(s) 2010. Liver specific transporters of microcystins as a tool to find novel inhibitors of OATP1B1 and OATP1B3.
  • Show author(s) 2009. Proteomic Unit at UoB (PROBE) The Norwegian Proteomics centre.
  • Show author(s) 2009. Possible side-chemistries with guanidino labeling strategies of C-terminal lysine‐peptides: Effect of different derivatization conditions.
  • Show author(s) 2009. Epac-induced changes in the proteome of human SH-SY5Y neuroblastoma cells.
  • Show author(s) 2007. Compartment modeling of nitric-oxide mediated activation of the cAMP-dependent protein kinase in platelets.
  • Show author(s) 2006. PROBE – nasjonal platform for proteomikk. NBS – Nytt 3/2006: 32-35.
  • Show author(s) 2005. Searching cyanobacteria and microalgae from Norwegian waters for drug candidates.
  • Show author(s) 2002. Effects of a new bioactive substance from a marine microalga on mammalian cells.
  • Show author(s) 2001. TWO NOVEL APOPTOSIS-MODULATION SUBSTANCES ISOLATED FROM MARINE MICRO-ALGAE.
  • Show author(s) 2001. New apoptosis-modulating substances from marine microalgae.
Academic literature review
  • Show author(s) 2020. The implementation of mass spectrometry-based proteomics workflows in clinical routines of acute myeloid leukemia: Applicability and perspectives. International Journal of Molecular Sciences. 1-23.
  • Show author(s) 2019. An overview on G protein-coupled receptor-induced signal transduction in acute myeloid leukemia. Current Medicinal Chemistry. 5293-5316.
  • Show author(s) 2017. Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers. Espert Review of Proteomics. 649-663.
  • Show author(s) 2011. The cAMP-dependent protein kinase pathway as therapeutic target - possibilities and pitfalls. Current Topics in Medicinal Chemistry. 1393-1405.
  • Show author(s) 2006. Proteomic and computational methods in systems modeling of cellular signaling. Current Pharmaceutical Biotechnology. 135-145.
  • Show author(s) 2006. Microcystin produces disparate effects on liver cells in a dose dependent manner. Mini-Reviews in Medicinal Chemistry. 279-285.

More information in national current research information system (CRIStin)